Publications by authors named "Carsten Goessl"

Claim this Profile
A
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products.
Mark D Stewart, Michael Kalos, Vicki Coutinho, Marc Better, Jonathan Jazayeri, Carsten Goessl

Cytotherapy· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Carsten Goessl

N Engl J Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Seock-Ah Im, Binghe Xu, Wei Li, Mark Robson, Quchang Ouyang, Carsten Goessl

Sci Rep· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Mark Robson, Kathryn J Ruddy, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Carsten Goessl

Eur J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Ruth Plummer, Henk M Verheul, Filip Y F L De Vos, Karin Leunen, L Rhoda Molife, Carsten Goessl

Adv Ther· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel Clarke, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Carsten Goessl

Lancet Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
Mark Robson, Carsten Goessl, Susan Domchek

N Engl J Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Carsten Goessl

N Engl J Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Karim Fizazi, Christophe Massard, Matthew Smith, Michael Rader, Janet Brown, Carsten Goessl

Eur Urol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Matthew R Smith, Fred Saad, Stephane Oudard, Neal Shore, Karim Fizazi, Carsten Goessl

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarcopenia during androgen-deprivation therapy for prostate cancer.
Matthew R Smith, Fred Saad, Blair Egerdie, Paul R Sieber, Teuvo L J Tammela, Carsten Goessl

J Clin Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Michael Rader, Carsten Goessl, Ze Cong

J Manag Care Pharm· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
Carsten Goessl, Leonid Katz, William C Dougall, Paul J Kostenuik, Holly Brenza Zoog

Ann N Y Acad Sci· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.
Allan Lipton, Matthew R Smith, Georgiana K Ellis, Carsten Goessl

Clin Med Insights Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Matthew R Smith, Fred Saad, Robert Coleman, Neal Shore, Karim Fizazi, Carsten Goessl

Lancet· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.
Matthew R Smith, Fred Saad, Blair Egerdie, Paul Sieber, Teuvo Lj Tammela, Carsten Goessl

J Bone Miner Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding horizons in metastatic prostate cancer treatment.
Karim Fizazi, Carsten Goessl

Nat Rev Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Karim Fizazi, Michael Carducci, Matthew Smith, Ronaldo Damião, Janet Brown, Carsten Goessl

Lancet· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
Allan Lipton, Carsten Goessl

Bone· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Matthew R Smith, Fred Saad, Blair Egerdie, Maciej Szwedowski, Teuvo L J Tammela, Carsten Goessl

J Urol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Matthew R Smith, Blair Egerdie, Narciso Hernández Toriz, Robert Feldman, Teuvo L J Tammela, Carsten Goessl

N Engl J Med· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Fred Saad, Richard Markus, Carsten Goessl

BJU Int· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Norio Kohno, Kenjiro Aogi, Hironobu Minami, Seigo Nakamura, Taro Asaga, Carsten Goessl

J Clin Oncol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
Matthew R Smith, Fairooz Kabbinavar, Fred Saad, Arif Hussain, Marc C Gittelman, Carsten Goessl

J Clin Oncol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of malignant spinal-cord compression.
Carsten Goessl

Lancet Oncol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis